Trial · NCT07887750
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
NCT07887750, Phase 1, Phase 2, Not yet recruiting, Regeneron Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs). Trials, record NCT07887750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
- NCT number
- NCT07887750
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 36 participants, estimated
- Lead sponsor
- Regeneron Pharmaceuticals
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- REGN9220, Odronextamab
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period | Up to 28 days | |
| Primary | Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Up to approximately 2 years | |
| Primary | Severity of TEAEs | Up to approximately 2 years | |
| Secondary | Concentration of REGN9220 in serum when given in combination with odronextamab | Up to approximately 2 years | |
| Secondary | Concentration of odronextamab in serum when given in combination with REGN9220 | Up to approximately 2 years | |
| Secondary | Occurrence of Anti-Drug Antibodies (ADA) to REGN9220 | Up to approximately 2 years | |
| Secondary | Magnitude of ADA to REGN9220 | Up to approximately 2 years | |
| Secondary | Occurrence of ADA to odronextamab | Up to approximately 2 years | |
| Secondary | Magnitude of ADA to odronextamab | Up to approximately 2 years | |
| Secondary | Best Overall Response (BOR) | Up to 90 days post last study drug administration |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887750
GET https://conductscience.org/api/trials/v1/NCT07887750/registered